Orphan drug program

Navigating orphan drug restrictions and accessing voluntary manufacturer pricing can be challenging and time-consuming. Our orphan drug program can help. We identify orphan drugs and proactively communicate with manufacturers to secure voluntary pricing on your behalf, so you can focus on what matters most.

Unlock value through enhanced orphan drug program

tep 1

NDC identification

Identify orphan drug NDCs for inclusion

Reporting and compliance

Provide reports to navigate restrictions and manage

documentation for HRSA and



Manufacturer outreach

Cencora pursues voluntary pricing contracts on behalf of entities affected by the orphan drug exclusion

If not successful, individual entity pursues voluntary pricing contracts

Contract loading

Cencora loads voluntary pricing into 340B accounts affected by the orphan drug exclusion

3D 3

How we can help

manufacturer audits

- Enhance compliance with documentation and reporting tools to navigate manufacturer restrictions and prepare for HRSA and/or manufacturer audits
- Leverage our reach to identify and facilitate contract requests on your behalf
- Make more informed business decisions with an updated list of orphan drugs covered by voluntary pricing contracts
- **Potentially save** on drug costs and eliminate administrative burden of managing orphan drug lists and ongoing contract negotiations



Millions in annualized savings



Hundreds of products with voluntary pricing



Dozens of manufacturer partners

To learn more, contact OrphanDrugSupport@amerisourcebergen.com